Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05020353
Other study ID # REACH - HIV - OraQuick - 2.0
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 21, 2022
Est. completion date December 2024

Study information

Verified date May 2024
Source Unity Health Toronto
Contact Sean B Rourke, PhD
Phone (416) 878-2779
Email sean.rourke@utoronto.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Oral fluid based HIV Self-testing (HIVST) provides another innovative and simple option to increase opportunities for HIV testing. At-home testing for HIV using oral fluid has been FDA approved and in use in the USA since 2012, and studies have also shown that interest and acceptability of HIVST with oral fluid is high in other global settings. However data for oral fluid based HIVST within key populations and those at high risk for HIV infection in Canada is limited. This study involves around 900 persons who are non-healthcare professionals and inexperienced in HIV self-testing (intended users) and are presenting at clinic sites across Canada for HIV testing. It will evaluate the accuracy (sensitivity and specificity), usability (persons performs test correctly) and readability (persons successfully interpret test results) of the OraQuick® HIV Self-Test when performed by persons representing intended users living in Canada. A final report of study results will be provided to the Test manufacturer for inclusion in the Health Canada license application process.


Description:

Background and Rationale: Self-testing for HIV is an approach with the potential to increase the access, uptake and frequency of HIV testing for those who may not otherwise test and remain undiagnosed. There is increasing evidence showing the acceptability and usability of HIV self-testing (HIVST) in various key populations. In 2016 the World Health Organization recommended HIVST as an alternative option to complement existing HIV testing opportunities. Since then, HIVST use has been scaling up rapidly; for example, Canada's first blood-based (fingerstick) HIV self-test was licensed for use in November 2020. Oral fluid based HIVST provides another innovative and simple option to increase opportunities for HIV testing. At-home testing for HIV using oral fluid has been FDA approved and in use in the USA since 2012, and studies have also shown that interest and acceptability of HIVST with oral fluid is high in other global settings. However data for oral fluid based HIVST within key populations and those at high risk for HIV infection in Canada is limited. Having a licensed oral fluid HIV self-test in addition to the licensed blood-based HIV self-test will allow individuals to choose what is best for them and increase the potential to reach the undiagnosed living with HIV. Objective: This study will evaluate the accuracy, usability (persons performs test correctly) and readability (persons successfully interpret test results) of the OraQuick® HIV Self-Test when performed by persons representing intended users living in Canada. Hypothesis: The OraQuick Self-test as performed by intended users (non-healthcare professional and inexperienced in HIV self-testing) will meet or exceed the accuracy, usability and label comprehension requirements from Health Canada for license as a Class IV in vitro diagnostic device for Canadian market entry. Study Design: This study was designed around the requirements set out in the Health Canada Guidance Document: "Guidance for Manufacturers of Human Immunodeficiency Virus (HIV) Rapid Diagnostic Tests (RDT's) for Use at Point of Care or Self Testing, 2017". It is an investigational device trial designed as a cross-sectional study which employs observational and interview-based methods. Sample population: The study population requirements published by Health Canada stipulates that the prospective study include: 900 lay persons with unknown HIV status including 400 persons at risk for HIV infection (e.g. intravenous drug users, men who have sex with men, etc.). Self-reported practices or behaviour will be used to define those at high risk. A minimum of 900 participants (non-healthcare professional and inexperienced in HIV self-testing) will read the instructions for use and conduct the OraQuick® HIV Self-Test. They will not be provided any training prior to use of the test. A trained healthcare provider or researcher (trained Observer) will watch, and document use of the test and independently read the participants self-test result. The participants will then complete a questionnaire to share their opinion on usability and label comprehension of this test. A minimum of 400 (of the 900) participants will also be provided five mock devices with different results and asked to interpret those results i.e. strong positive; weak positive, negative, invalid with no control and no test line, and invalid with no control and a positive test line. This will evaluate readability of this test. All participants will also have a venous blood sample collected for testing of plasma at a central laboratory with a 4th generation (Ag/Ab combo) HIV enzyme immunoassay that will serve as the comparator method (laboratory reference testing). All self-tests will be confirmed using a Canadian standard HIV testing algorithm. The sensitivity and specificity of the self-test result will be calculated relative to the "clinical truth" of the participants' HIV status determined by the confirmatory test process, where applicable. Participants will be instructed to return to the clinic for a follow-up visit, two (2) weeks after self-testing to obtain their laboratory test results which will be their official result. Study Intervention Details: Participants will be recruited to the study when they come in for voluntary HIV testing (e.g. POC testing) at a minimum of 3 study sites (different geographic locations). If persons consent to participating, all those enrolled will voluntarily complete a questionnaire (collecting demographics and HIV medical history information) and then provide their venous whole blood sample (for standard of care, laboratory confirmatory testing and comparator method), complete the OraQuick® HIV Self-Test (read test instructions, sample collection, sample testing, result interpretation), complete mock result interpretation, and complete questionnaires - Visit 1 (day 1; about 60 minutes). All patients will be instructed to return to the clinic for a follow-up visit two (2) weeks later to obtain their laboratory test results (Visit 2; about 15 - 60 minutes), post -test counselling, and to be linked to appropriate care depending on the test results.. Patients may also have a point-of-care (POC) test conducted on site as part of the clinic's standard of care testing, outside of the protocol and after all study procedures for Visit 1 are completed.


Recruitment information / eligibility

Status Recruiting
Enrollment 900
Est. completion date December 2024
Est. primary completion date September 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Are 18 years of age and older - Are able to speak / read / write English or French - Have presented for voluntary testing for HIV infection in the clinic or community based setting - Are willing to participate in the study site's standard of care HIV counselling and testing program and receive the study site's standard of care test results - Are willing to be a participant in the study - Are able to provide informed consent i.e. understands and signs the informed consent form - Are able to complete the required testing on the allocated testing day - Are willing to provide the necessary oral fluid and venipuncture blood for use in the study protocol testing methods. - Are of unknown HIV status (last HIV negative test must be a minimum of 3 months prior) Exclusion Criteria: - Do not meet all the inclusion criteria - Are known HIV positive - Are on antiretroviral therapy (ART) or anti-HIV medications for the treatment of HIV, either as pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) or experimental vaccine - Have any experience or have ever conducted a rapid diagnostic self-test for HIV or any other sexually transmitted and blood borne illnesses disease - Are currently participating in a concurrent trial of HIV self-tests - Are investigator site employees or immediate family members of sponsor or investigator site employee - Are a practicing medical healthcare professional (doctor, nurse or HIV counsellor that performs HIV testing with Rapid Tests) - Any condition which, in the opinion of the Observer, would make the participant unsuitable or unsafe for enrolment or could interfere with the completion of the assessment and questionnaire etc. or bias the outcome, e.g. being unable to see / read by forgetting to bring reading glasses, being intoxicated, acute sickness, visibly distressed.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
OraQuick® HIV Self-Test
OraQuick® HIV Self-Test in oral fluid conducted by observed intended users (non-healthcare professional and inexperienced in HIV self-testing) compared to laboratory 4th generation Ag/Ab enzyme immunoassay (EIA) results performed on venous blood.

Locations

Country Name City State
Canada Clinique médicale l'Actuel Montreal Quebec
Canada ByWard Family Health Team Ottawa Ontario
Canada Hassle Free Clinic Toronto Ontario
Canada Maple Leaf Research Toronto Ontario
Canada Women's Health in Women's Hands Community Health Centre Toronto Ontario
Canada Cool Aid Community Health Centre Vancouver British Columbia
Canada Nine Circles Community Health Centre Winnipeg Manitoba

Sponsors (2)

Lead Sponsor Collaborator
Unity Health Toronto Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Device Performance Sensitivity and specificity of study participants' self-interpreted self-test results with the OraQuick® HIV Self-Test versus the HIV status as determined by the 4th generation EIA and confirmatory testing for HIV as necessary. 6 - 12 months
Primary Usability Observation to determine if participants perform all critical steps correctly 6 - 12 months
Primary Readability or Interpretation Confirmation by Observer to determine if participant interprets test results correctly and successful interpretation of various contrived (mock) test device results. 6 - 12 months
Primary Label Comprehension To determine that the participant is aware of key messages in labelling including test limitations and what to do following the test result. 6 - 12 months
Secondary Secondary efficacy analysis Secondary efficacy analysis may be performed for sub-groups (e.g. age, language, education and literacy levels, risk factors and populations) for each specificity and sensitivity. 6 - 12 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2